Westlake Village, CA / San Diego, CA, January 2, 2026 – FlemingMartin is pleased to announce that Genelux, a late clinical-stage immuno-oncology company, has hired Jason Litten to be their new Chief Medical Officer.

Further information can be found here: Jason Litten Press Release

Redefining immuno-oncology, Genelux (NASDAQ: GNLX) is a late clinical-stage biopharmaceutical company focused on developing a pipeline of next-generation oncolytic immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. The core of Genelux’s discovery and development efforts revolves around its proprietary CHOICE™ platform from which the company has developed an extensive library of isolated and engineered oncolytic vaccinia virus immunotherapeutic product candidates, including Olvi-Vec. Learn more at genelux.com.

FlemingMartin is a retained executive search firm focused on building exceptional teams in the Technology and Life Sciences sectors. We partner with CEOs, Boards, and Venture Capital as trusted advisors who enable companies to gain powerful, far-reaching, and lasting contributions from their executive-level human capital. Learn more at flemingmartin.com.